Menu
ncarol.com
  • Home
  • Books
  • Book Release
  • Health
  • Business
  • Financial
  • Arts
  • Manufacturing
  • Real Estate
ncarol.com

Blaming Patients: How Failed Treatments Fuel a $51 Billion Brain Device Industry
ncarol.com/10291948

Trending...
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
CCHR's New Report Exposes Dangerous Devices
CCHR's New Report Exposes Dangerous Neurological Interventions Being Pushed on Veterans, Children, and the Vulnerable

LOS ANGELES - ncarol.com -- The Citizens Commission on Human Rights International (CCHR), a leading mental health industry watchdog, has released a damning report detailing how psychiatry is blaming patients—rather than failed treatments—to justify a surge in brain stimulation interventions. "When psychiatric drugs and therapy don't work, psychiatry rarely blames the treatment—it blames the patient, saying they are 'treatment-resistant,'" said Jan Eastgate, President of CCHR International. "'Treatment-resistant' isn't a diagnosis—it's a deflection. And it's being used to push invasive procedures like Electroconvulsive Therapy (ECT), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and Transcranial Magnetic Stimulation (TMS)."

These brain stimulation devices were "cleared" by the Food and Drug Administration (FDA) or approved under Humanitarian Device Exemptions, bypassing the rigorous testing normally required of most medical devices. Many were greenlighted based on the device delivering ECT—a practice known for causing brain damage, memory loss, and even death[1].

Even industry insiders acknowledge concerns. "The precise physiological mechanisms of DBS are not yet fully understood," admits one clinical review.[2]  A professor of psychiatry at Brown University's Alpert Medical School, put it more starkly: "This really is a kind of mind control."[3]

The term "treatment-resistant" is a psychiatric sleight of hand, Eastgate says, now used to justify a global neurostimulation industry projected to hit $51 billion by 2030. Labeling up to 60% of psychiatric patients as "resistant" creates a false pretext for experimental interventions.[4] Meanwhile, 25% of patients develop psychotropic drug tolerance within weeks, prompting ever-riskier "solutions."[5]

Electroshock: Psychiatry's Recycled Blunder

ECT involves sending up to 460 volts through the brain to trigger seizures. Contrary to PR spin, Eastgate says, experts report modern ECT is no safer—voltage levels are higher than when broken bones were common due to convulsions.
  • FDA Loophole: Grandfathered in without clinical trials in 1976. In 2018, the FDA reclassified some ECT uses as "low risk," even for children as young as 13. Over 2,400 public comments opposed this.
  • Global Condemnation: The World Health Organization and United Nations consider ECT on children or the non-consenting a form of torture.[6]
  • Medical Harm: Neurologists equate ECT's effects to traumatic brain injury.[7] Patients are 44 times more likely to die by suicide than the general population. One in 15 ECT patients face life-threatening cardiac issues.[8]
  • Financial Cost: A $3–5.4 billion industry. Medicaid spent $9 million on ECT in 2023 in 27 states.[9] The VA and Department of Defense have administered it to veterans and children under age five.[10]

Deep Brain Stimulation: Electrodes are surgically implanted into the brain, powered by a device in the chest.
  • FDA Fast Track: Approved via Humanitarian Device Exemption for OCD in 2009 without efficacy data.
  • Harms: Stroke, hemorrhage, hallucinations, sexual dysfunction, apathy, and suicide attempts.[11]
  • Patient Testimonies: Participants in failed DBS trials report cognitive decline and emotional deterioration.[12]

Vagus Nerve Stimulation: Electrical stimulation delivered via electrodes wrapped around the vagus nerve.
  • FDA: Approved in 2005 for "treatment-resistant depression" despite lacking robust evidence.
  • Risks: Nerve damage, infection, hoarseness, breathing difficulty. The FDA has logged over 10,000 complaints involving death, injury, or device malfunction.[13]
  • Cost: Averaging $30,000+.

Transcranial Magnetic Stimulation: Magnetic pulses are aimed at the brain over six weeks.
  • Youth Approval: Cleared in 2008 for adults, and in 2024 for adolescents as young as 15.
  • Side Effects: "Brain fog," seizures, mood swings. One patient said: "This treatment destroyed my life… It gave me false hope."[14]
  • Price Tag: Up to $300 per session; full courses can reach $15,000.

Despite the sophistication of these procedures, there is still no objective medical test to diagnose any psychiatric disorder. No blood test. No brain scan. No biomarker.[15]

More on ncarol.com
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • 'Reflections: Enlightening Insights Into the Divine Mystery' — The Latest Book by Philosopher Steven Colborne
  • Scott G. Hoy of Hoy Law Earns 11th Consecutive Super Lawyers Selection
  • L2 Aviation Selected for U.S. Air Force KC-46 CASPER Multiple Award Contract
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH

Dr. Thomas Insel, former director of the National Institute for Mental Health advised: "Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM [Diagnostic and Statistical Manual of Mental Disorders] diagnoses are based on a consensus… not any objective laboratory measure."[16]

"It's not the patient that's resistant—it's the system that's resistant to accountability," Eastgate said. "In any other field, if the intervention failed, the treatment would be reevaluated. But psychiatry doubles down, pushing more dangerous interventions instead."

CCHR urges policy makers to: End all use of ECT and brain stimulation devices for treatment of mental issues, and end ECT's role as a predicate device for newer technologies. And support humane, non-invasive, non-drug, non-brain stimulation solutions that respect patient dignity and avoid neurological and other physical harm.

CCHR, established in 1969 by the Church of Scientology and psychiatrist Dr. Thomas Szasz has a record of reforms that include banning lethal Deep Sleep Treatment, outlawing ECT use on children in several U.S. states, and securing global recognition for patient rights. Today, the United Nations and WHO echo what CCHR has long fought for: coercion has no place in mental health care.

Sources:

[1] FDA, Final Rule on Electroconvulsive Therapy Devices, Federal Register, Dec. 26, 2018; WHO-OHCHR, "Guidance on Mental Health, Human Rights and Legislation," 9 Oct. 2023, p. 58, www.ohchr.org/sites/default/files/documents/publications/WHO-OHCHR-Mental-health-human-rights-and-legislation_web.pdf

[2] Lavanya P. Sharma, et. al, "Deep brain stimulation – A primer for psychiatrists," Asian Journal of Psychiatry, Vol. 104, Feb. 2025

[3] Lavanya P. Sharma, et. al, "Deep brain stimulation – A primer for psychiatrists," Asian Journal of Psychiatry, Vol. 104, Feb. 2025

[4] "Treatment resistance in psychiatry: state of the art and new directions," Mol Psychiatry, July 2021, pmc.ncbi.nlm.nih.gov/articles/PMC8960394/#fn-group1

[5] pmc.ncbi.nlm.nih.gov/articles/PMC9332474/

[6] WHO- OHCHR, "Guidance on Mental Health, Human Rights and Legislation," 9 Oct. 2023, pp. 15, 58 and 59; www.cchrint.org/2023/09/18/who-guideline-condemns-coercive-psychiatric-practices/

[7] "Electroconvulsive Shock Therapy Lawsuit – What You Should Know About ECT," www.wisnerbaum.com/defective-medical-device-injuries/ect/

[8] www.cchrint.org/2024/11/08/veterans-day-cchr-calls-for-safeguards/, Peter Simons, "ECT Does Not Seem to Prevent Suicide," Mad In America, 17 Feb. 2023, www.madinamerica.com/2023/02/ect-does-not-seem-to-prevent-suicide/

More on ncarol.com
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • KeysCaribbean Resorts Offer Savings On Summer Vacations Now Through Aug. 31
  • Crossroads4Hope Announces The Lipschutz Women's Fund
  • Handmade Coverlet Returns Home to Piedmont Crossing
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)

[9] www.cchrint.org/2024/08/23/the-collapse-of-electroshock/ Based on Freedom of Information Requests to 27 states

[10] www.cchrint.org/2018/10/12/veterans-get-damaging-mental-health-deal/; Tricare Encounter Data (TED) Non-Institutional (Outpatient) for Purchased Care claims, Data Extract as of 10/21/2016, Data received from CCHR International Freedom of Information Request, 2016

[11] "Brain Stimulation Therapies," NIMH, www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml, accessed 21 Feb. 2011; Dr. Ananya Mandal, MD, "Deep Brain Stimulation Side Effects," News Medical Life Sciences, 22 July 2023, www.news-medical.net/health/Deep-Brain-Stimulation-Side-Effects.aspx

[12] Danielle Egan, "Adverse Effects: The Perils of Deep Brain Stimulation for Depression," Mad in America, 24 Sept. 2015

[13] www.hg.org/legal-articles/patients-with-complications-from-cyberonics-vns-therapy-systems-may-qualify-to-file-a-lawsuit-49467

[14] FDA MAUDE report, Neurostar TMS, 07/14/2021, www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=15283600&pc=OBP

[15] www.sciencedaily.com/releases/2020/08/200817104247.htm

[16] psychrights.org/2013/130429NIMHTransformingDiagnosis.htm

Contact
CCHR International
***@cchr.org


Source: Citizens Commission on Human Rights International
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
  • NVM Pet Announces Leadership Transition, Promotes Next Generation of Executive Leadership
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Valgar LLC Launches The Briefing Room: Education Leaders
  • New from Regal House Publishing, St. Ulphia's Dead, a dark comedy in the magical realist tradition
  • New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
  • New Research Puts the Cost of Enterprise Decision Delay at $630 Billion a Year Across the Global 2000
  • Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine
  • Lineus Medical Signs Partnership Agreement with DIMA MedTech to Support Expansion into Italy
  • New Research: Deterministic Decompilation of Hermes Bytecode Back to Readable JavaScript
  • Lionheart Holdings and KEO Energy Sign Letter of Intent for Proposed Business Combination
  • First Flight Society Celebrates National Aviation Day 2026 on Wednesday, August 19th
  • Marcus Christ Announces Singles: "The Hammer Goes Click" and "You Hate Me, I Hate You"
  • Nina Simone and Samuel Waymon Music Scholarship Fund Opens 2026/27 Application Cycle
  • Fatal FOMO May be Your Last Roll of the Dice
  • Inlow Upholstery Offers Dining Chair Reupholstery for Cleveland County Homeowners
  • Financial Visionary Kevin Foushee Expands Impact Through MTM LLC and Client-First Advisory Services
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
_catLbl0 _catLbl1

Popular on ncarol.com

  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project - 148
  • BumblebeeSmart Announces Partnership with Extreme Kids World to Expand Access to Sensory Wall Panels and Educational Busy Boards - 113
  • Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers - 108
  • UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch - 105
  • OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
  • Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
  • Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
  • Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree

Similar on ncarol.com

  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • L2 Aviation Selected for U.S. Air Force KC-46 CASPER Multiple Award Contract
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • KeysCaribbean Resorts Offer Savings On Summer Vacations Now Through Aug. 31
  • Crossroads4Hope Announces The Lipschutz Women's Fund
  • Handmade Coverlet Returns Home to Piedmont Crossing
  • VINCE Lifestyle Magazine Announces Virtual "Health, Wealth & Wellness Summit"
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • CRG Awarded NASA SEWP VI Contracts in Categories B and C
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute